Drug-induced pulmonary artery hypertension

Pulmonary arterial hypertension is a condition characterized by an increase in mean pressure in the pulmonary artery. This pathology is associated with high mortality, and specific therapy for pulmonary arterial hypertension does not affect the cause of the disease and is extremely expensive. In this regard, it is especially important to study the modifiable etiological factors of pulmonary arterial hypertension. One such factor is drugs. One of the leading groups of drugs-inductors is anorexigenic drugs. It was the representatives of this group, such as aminorex, who were the first inducers of pulmonary hypertension. Moreover, this adverse reaction was so significant that it led to the withdrawal of these drugs. Currently, the leading role in the context of drug-induced pulmonary hypertension is played by such drugs as anticancer, antiviral drugs, and interferons. These drugs lead to pulmonary hypertension through various pathophysiological mechanisms. The leading measures to prevent this pathology are to limit the use of culprit medications, reduce the spread of HIV infection, since several groups of drugs can be used to treat HIV-infected patients, leading to the development of pulmonary hypertension.

1. Avdeev SN, Barbarash OL, Bautin AE, Volkov AV, Veselova TN, Galyavich AS, Goncharova NS, Gorbachevsky SV, Danilov NM, Eremenko AA, Martynyuk TV, Moiseeva OM, Saidova MA, Sergienko VB, Simakova MA, Stukalova OV, Chazova IE, Chernyavsky AM, Shalaev SV, Shmalts AA, Tsareva NA. 2020 Clinical practice guidelines for Pulmonary hypertension, including chronic thromboembolic pulmonary hypertension. Russian Journal of Cardiology. 2021;26(12):4683. (In Russ). doi:10.15829/1560-4071-2021-4683

2. Kovacs G, Berghold A, Scheidl S, Olschewski H. Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review. Eur Respir J. 2009;34(4):888–94. doi:10.1183/09031936.00145608

3. Thenappan T, Ryan JJ, Archer SL. Evolving epidemiology of pulmonary arterial hypertension [published correction appears in Am J Respir Crit Care Med. 2013;187(3):333]. Am J Respir Crit Care Med. 2012;186(8):707–9. doi:10.1164/rccm.201207-1266ED

4. Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37(1):67–119. doi:10.1093/eurheartj/ehv317

5. Zelt JGE, Sugarman J, Weatherald J, et al. Mortality trends in pulmonary arterial hypertension in Canada: a temporal analysis of survival per ESC/ERS Guideline Era [published online ahead of print, 2021 Oct 21]. Eur Respir J. 2021;2101552. doi:10.1183/13993003.01552-2021

6. Thenappan T, Ormiston ML, Ryan JJ, Archer SL. Pulmonary arterial hypertension: pathogenesis and clinical management. BMJ. 2018;360:j5492. doi:10.1136/bmj.j5492

7. Anand V, Roy SS, Archer SL, et al. Trends and Outcomes of Pulmonary Arterial Hypertension-Related Hospitalizations in the United States: Analysis of the Nationwide Inpatient Sample Database From 2001 Th rough 2012. JAMA Cardiol. 2016;1(9):1021–9. doi:10.1001/jamacardio.2016.3591

8. Helgeson SA, Menon D, Helmi H, et al. Psychosocial and Financial Burden of Therapy in USA Patients with Pulmonary Arterial Hypertension. Diseases. 2020;8(2):22. doi:10.3390/diseases8020022

9. McGee M, Whitehead N, Martin J, Collins N. Drug-associated pulmonary arterial hypertension. Clin Toxicol (Phila). 2018;56(9):801–9. doi:10.1080/15563650.2018.1447119

10. Correale M, Tricarico L, Grazioli D, et al. Drug-Induced Pulmonary Arterial Hypertension: Mechanisms and Clinical Management. Cardiovasc Drugs Ther. 2019;33(6):725–38. doi:10.1007/s10557-019-06920-x

11. Ramirez RL 3rd, Pienkos SM, de Jesus Perez V, Zamanian RT. Pulmonary Arterial Hypertension Secondary to Drugs and Toxins. Clin Chest Med. 2021;42(1):19–38. doi:10.1016/j.ccm.2020.11.008

12. Weigle DS. Pharmacological therapy of obesity: past, present, and future. J Clin Endocrinol Metab. 2003;88(6):2462–9. doi:10.1210/jc.2003-030151

13. Abenhaim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med. 1996;335(9):609–16. doi:10.1056/NEJM199608293350901

14. Dempsie Y, MacRitchie NA, White K, et al. Dexfenfluramine and the oestrogen-metabolizing enzyme CYP1B1 in the development of pulmonary arterial hypertension. Cardiovasc Res. 2013;99(1):24–34. doi:10.1093/cvr/cvt064

15. Savale L, Chaumais MC, Cottin V, et al. Pulmonary hypertension associated with benfluorex exposure. Eur Respir J. 2012;40(5):1164–72. doi:10.1183/09031936.00188611

16. Chen PI, Cao A, Miyagawa K, et al. Amphetamines promote mitochondrial dysfunction and DNA damage in pulmonary hypertension. JCI Insight. 2017;2(2):e90427. doi:10.1172/jci.insight.90427

17. Terra Filho M, Yen CC, Santos Ude P, Muñoz DR. Pulmonary alterations in cocaine users. Sao Paulo Med J. 2004;122(1):26–31. doi:10.1590/s1516-31802004000100007

18. Savale L, Sattler C, Günther S, et al. Pulmonary arterial hypertension in patients treated with interferon [published correction appears in Eur Respir J. 2015;46(6):1854]. Eur Respir J. 2014;44(6):1627–34. doi:10.1183/09031936.00057914

19. Caravita S, Secchi MB, Wu SC, Pierini S, Paggi A. Sildenafil therapy for interferon-β-1a-induced pulmonary arterial hypertension: a case report. Cardiology. 2011;120(4):187–9. doi:10.1159/000335064

20. Shah NP, Wallis N, Farber HW, et al. Clinical features of pulmonary arterial hypertension in patients receiving dasatinib. Am J Hematol. 2015;90(11):1060–4. doi:10.1002/ajh.24174

21. Minami M, Arita T, Iwasaki H, et al. Comparative analysis of pulmonary hypertension in patients treated with imatinib, nilotinib and dasatinib. Br J Haematol. 2017;177(4):578–87. doi:10.1111/bjh.14608

22. Hickey PM, Thompson AA, Charalampopoulos A, et al. Bosutinib therapy resulting in severe deterioration of pre-existing pulmonary arterial hypertension. Eur Respir J. 2016;48(5):1514–6. doi:10.1183/13993003.01004-2016

23. Quilot FM, Georges M, Favrolt N, et al. Pulmonary hypertension associated with ponatinib therapy. Eur Respir J. 2016;47(2):676–9. doi:10.1183/13993003.01110-2015

24. Low AT, Howard L, Harrison C, Tulloh RM. Pulmonary arterial hypertension exacerbated by ruxolitinib. Haematologica. 2015;100(6):e244–5. doi:10.3324/haematol.2014.120816

25. Gagnadoux F, Capron F, Lebeau B. Pulmonary veno-occlusive disease after neoadjuvant mitomycin chemotherapy and surgery for lung carcinoma. Lung Cancer. 2002;36(2):213–5. doi:10.1016/s0169-5002(01)00479-2

26. Ranchoux B, Günther S, Quarck R, et al. Chemotherapyinduced pulmonary hypertension: role of alkylating agents. Am J Pathol. 2015;185(2):356–71. doi:10.1016/j.ajpath.2014.10.021

27. Lafaras C, Mandala E, Verrou E, et al. Non-thromboembolic pulmonary hypertension in multiple myeloma, after thalidomide treatment: a pilot study. Ann Oncol. 2008;19(10):1765–9. doi:10.1093/annonc/mdn287

28. Liotta M, Rose PG, Escobar PF. Pulmonary hypertension in two patients treated with bevacizumab for recurrent ovarian cancer. Gynecol Oncol. 2009;115(2):308–9. doi:10.1016/j.ygyno.2009.08.003

29. Hainsworth JD, Fang L, Huang JE, et al. BRIDGE: an open-label phase II trial evaluating the safety of bevacizumab + carboplatin/paclitaxel as first-line treatment for patients with advanced, previously untreated, squamous non-small cell lung cancer. J Thorac Oncol. 2011;6(1):109–14. doi:10.1097/JTO.0b013e3181f94ad4

30. Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension [published correction appears in J Am Coll Cardiol. 2014;63(7):746]. J Am Coll Cardiol. 2013;62(25 Suppl):D34–D41. doi:10.1016/j.jacc.2013.10.029

31. Mathew R, Huang J, Katta US, Krishnan U, Sandoval C, Gewitz MH. Immunosuppressant-induced endothelial damage and pulmonary arterial hypertension. J Pediatr Hematol Oncol. 2011;33(1):55–8. doi:10.1097/MPH.0b013e3181ec0ede

32. Alvarez PA, Saad AK, Flagel S, Mazzocchi O, Blanco MV. Leflunomide-induced pulmonary hypertension in a young woman with rheumatoid arthritis: a case report. Cardiovasc Toxicol. 2012;12(2):180–3. doi:10.1007/s12012-012-9153-3

33. Lazarevic VLj, Liljeholm M, Forsberg K, et al. Fludarabine, cyclophosphamide and rituximab (FCR) induced pulmonary hypertension in Waldenstrom macroglobulinemia. Leuk Lymphoma. 2008;49(6):1209–11. doi:10.1080/10428190802007718

34. Montrone D, Correale M, Franzese MG, Ieva R, Di Biase M, Capalbo SF. Pulmonary arterial hypertension in a chronic lymphocytic leukemia patient in treatment with rituximab. J Cardiovasc Med (Hagerstown). 2015;16(Suppl 1):S65. doi:10.2459/JCM.0b013e3283621adf

35. Ho RC, Ho EC, Tan CH, Mak A. Pulmonary hypertension in first episode infective endocarditis among intravenous buprenorphine users: case report. Am J Drug Alcohol Abuse. 2009;35(3):199–202. doi:10.1080/00952990902939719

36. Garrett PM. Tramadol overdose and serotonin syndrome manifesting as acute right heart dysfunction. Anaesth Intensive Care. 2004;32(4):575–7. doi:10.1177/0310057X0403200417

37. Freitas CF, Faro R, Dragosavac D, Clozel M, De Nucci G, Antunes E. Role of endothelin-1 and thromboxane A2 in the pulmonary hypertension induced by heparin-protamine interaction in anesthetized dogs. J Cardiovasc Pharmacol. 2004;43(1):106–12. doi:10.1097/00005344-200401000-00016

38. Evrard F, Dupuis M, Muller T, Jacquerye P. Hypertension artérielle pulmonaire isolée et pergolide [Isolated pulmonary hypertension and pergolide]. Rev Neurol (Paris). 2008;164(3):278–9. doi:10.1016/j.neurol.2007.09.005

39. Walker AM, Langleben D, Korelitz JJ, et al. Temporal trends and drug exposures in pulmonary hypertension: an American experience. Am Heart J. 2006;152(3):521–6. doi:10.1016/j.ahj.2006.02.020

40. Misumi K, Ogo T, Ueda J, et al. Development of Pulmonary Arterial Hypertension in a Patient Treated with Qing-Dai (Chinese Herbal Medicine). Intern Med. 2019;58(3):395–9. doi:10.2169/internalmedicine.1523-18

41. Tisdale JE, Miller DA. Drug Induced Diseases: Prevention, Detection, and Management. 3rd Ed. Bethesda, Md.: American Society of Health-System Pharmacists, 2018. 1399 рр.

42. Hoeper MM, Ghofrani HA, Grünig E, et al. Pulmonary Hypertension. Dtsch Arztebl Int. 2017;114(5):73–84. doi:10.3238/arztebl.2017.0073

43. Quezada M, Martin-Carbonero L, Soriano V, et al. Prevalence and risk factors associated with pulmonary hypertension in HIV-infected patients on regular follow-up. AIDS. 2012;26(11):1387–92. doi:10.1097/QAD.0b013e328354f5a1

44. Rasoulinejad M, Moradmand Badie S, Salehi MR, et al. Echocardiographic assessment of systolic pulmonary arterial pressure in HIV-positive patients. Acta Med Iran. 2014;52(11):827–30.

45. Orcholski ME, Yuan K, Rajasingh C, et al. Drug-induced pulmonary arterial hypertension: a primer for clinicians and scientists. Am J Physiol Lung Cell Mol Physiol. 2018;314(6):L967–L983. doi:10.1152/ajplung.00553.2017

46. MacLean MMR. The serotonin hypothesis in pulmonary hypertension revisited: targets for novel therapies (2017 Grover Conference Series). Pulm Circ. 2018;8(2):2045894018759125. doi:10.1177/2045894018759125

47. Hood KY, Mair KM, Harvey AP, et al. Serotonin Signaling Through the 5-HT1B Receptor and NADPH Oxidase 1 in Pulmonary Arterial Hypertension. Arterioscler Thromb Vasc Biol. 2017;37(7):1361–70. doi:10.1161/ATVBAHA.116.308929

48. Maclean MR, Dempsie Y. Th e serotonin hypothesis of pulmonary hypertension revisited. Adv Exp Med Biol. 2010;661:309–22. doi:10.1007/978-1-60761-500-2_20

49. Bregel LV, Belozerov YuM, Novikov PV, Shkolnikova MA. The genetics of pulmonary hypertension. Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics). 2014;59(1):22–7. (In Russ).

50. Pleym H, Greiff G, Mjorndal T, et al. Effect of serotonin reuptake inhibitors on pulmonary hemodynamics in humans. J Clin Med Res. 2011;3(5):230–8. doi:10.4021/jocmr654w

51. Guignabert C, Izikki M, Tu LI, et al. Transgenic mice overexpressing the 5-hydroxytryptamine transporter gene in smooth muscle develop pulmonary hypertension. Circ Res. 2006;98(10):1323–30. doi:10.1161/01.RES.0000222546.45372.a0

52. Adnot S, Houssaini A, Abid S, et al. Serotonin transporter and serotonin receptors. Handb Exp Pharmacol. 2013;218:365–80. doi:10.1007/978-3-642-38664-0_15

53. Dempsie Y, MacLean M. Role of the serotonin transporter in pulmonary arterial hypertension. Expert Rev Clin Pharmacol. 2008;1(6):749–57. doi:10.1586/17512433.1.6.749

54. Eddahibi S, Adnot S. Anorexigen-induced pulmonary hypertension and the serotonin (5-HT) hypothesis: lessons for the future in pathogenesis. Respir Res. 2002;3(1):9. doi:10.1186/rr181

55. MacLean MR. Pulmonary hypertension, anorexigens and 5-HT: pharmacological synergism in action? Trends Pharmacol Sci. 1999;20(12):490–5. doi:10.1016/s0165-6147(99)01389-9

56. Hendricks-Munoz KD, Gerrets RP, Higgins RD, et al. Cocaine-stimulated endothelin-1 release is decreased by angiotensin-converting enzyme inhibitors in cultured endothelial cells. Cardiovasc Res. 1996;31(1):117–23. doi:10.1016/s0008-6363(95)00168-9

57. Pradhan L, Mondal D, Chandra S, et al. Molecular analysis of cocaineinduced endothelial dysfunction: role of endothelin-1 and nitric oxide. Cardiovasc Toxicol. 2008;8(4):161–71. doi:10.1007/s12012-008-9025-z

58. George PM, Cunningham ME, Galloway-Phillipps N, et al. Endothelin-1 as a mediator and potential biomarker for interferon induced pulmonary toxicity. Pulm Circ. 2012;2(4):501–4. doi:10.4103/2045-8932.105039

59. Moslehi JJ, Deininger M. Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia. J Clin Oncol. 2015;33(35):4210–8. doi:10.1200/JCO.2015.62.4718

60. Groeneveldt JA, Gans SJ, Bogaard HJ, Vonk-Noordegraaf A. Dasatinibinduced pulmonary arterial hypertension unresponsive to PDE-5 inhibition. Eur Respir J. 2013;42(3):869–70. doi:10.1183/09031936.00035913

61. Ranchoux B, Meloche J, Paulin R, et al. DNA Damage and Pulmonary Hypertension. Int J Mol Sci. 2016;17(6):990. doi:10.3390/ijms17060990

62. Brown JM, Yamamoto BK. Effects of amphetamines on mitochondrial function: role of free radicals and oxidative stress. Pharmacol Ther. 2003;99(1):45–53. doi:10.1016/s0163-7258(03)00052-4

63. Orcholski ME, Khurshudyan A, Shamskhou EA, et al. Reduced carboxylesterase 1 is associated with endothelial injury in methamphetamineinduced pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol. 2017;313(2):L252–L266. doi:10.1152/ajplung.00453.2016

64. Guignabert C, Phan C, Seferian A, et al. Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension. J Clin Invest. 2016;126(9):3207–18. doi:10.1172/JCI86249

65. Li S, Yu Y, Yang P, et al. Trichloroethylene Alters Th 1/Th 2/Th 17/Treg Paradigm in Mice: A Novel Mechanism for Chemically Induced Autoimmunity. Int J Toxicol. 2018;37(2):155–63. doi:10.1177/1091581818757036

66. Burton VJ, Ciuclan LI, Holmes AM, et al. Bone morphogenetic protein receptor II regulates pulmonary artery endothelial cell barrier function. Blood. 2011;117(1):333–41. doi:10.1182/blood-2010-05-285973

67. Huertas A, Perros F, Tu L, et al. Immune dysregulation and endothelial dysfunction in pulmonary arterial hypertension: a complex interplay. Circulation. 2014;129(12):1332–40. doi:10.1161/CIRCULATIONAHA.113.004555

68. Joselson R, Warnock M. Pulmonary veno-occlusive disease after chemotherapy. Hum Pathol. 1983;14(1):88–91. doi:10.1016/s0046-8177(83)80052-5

69. Wu KY, Wang HZ, Hong SJ. Mechanism of mitomycin-induced apoptosis in cultured corneal endothelial cells. Mol Vis. 2008;14:1705–12.

70. Kanmogne GD, Kennedy RC, Grammas P. Analysis of human lung endothelial cells for susceptibility to HIV type 1 infection, coreceptor expression, and cytotoxicity of gp120 protein. AIDS Res Hum Retroviruses. 2001;17(1):45–53. doi:10.1089/088922201750056771

71. Mehta PM, Grainger TA, Lust RM, et al. Effect of cocaine on left ventricular function. Relation to increased wall stress and persistence after treatment. Circulation. 1995;91(12):3002–9. doi:10.1161/01.cir.91.12.3002

72. Russian Society of Cardiology (RSC). 2020 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology. 2020;25(11):4083. (In Russ). doi:10.15829/1560-4071-2020-4083

73. Savale L, Chaumais MC, O’Connell C, et al. Interferon-induced pulmonary hypertension: an update. Curr Opin Pulm Med. 2016;22(5):415–20. doi:10.1097/MCP.0000000000000307

74. Renard S, Borentain P, Salaun E, et al. Severe Pulmonary Arterial Hypertension in Patients Treated for Hepatitis C With Sofosbuvir. Chest. 2016;149(3):e69–e73. doi:10.1016/j.chest.2015.09.018

75. Dhillon S, Kaker A, Dosanjh A, et al. Irreversible pulmonary hypertension associated with the use of interferon alpha for chronic hepatitis C. Dig Dis Sci. 2010;55(6):1785–90. doi:10.1007/s10620-010-1220-7

76. Funakoshi-Hirose I, Aki T, Unuma K, et al. Distinct effects of methamphetamine on autophagy-lysosome and ubiquitin-proteasome systems in HL-1 cultured mouse atrial cardiomyocytes. Toxicology. 2013;312:74–82. doi:10.1016/j.tox.2013.07.016

77. Humbert M, Deng Z, Simonneau G, et al. BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives. Eur Respir J. 2002;20(3):518–23. doi:10.1183/09031936.02.01762002

78. Naranjo C, Busto U, Sellers E, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–45. doi:10.1038/clpt.1981.154

79. Sychev DA, Ostroumova OD, Pereverzev AP, et al. Drug-induced diseases: approaches to diagnosis, correction and prevention. Pharmacovigilance. Farmateka. 2020;(6):113–26. (In Russ). doi:10.18565/pharmateca.2020.6.113-126

80. Lekarstvenno-inducirovannye zabolevaniya. Tom I: monografiya / VA Dyo, KA Zagorodnikova, DV Ivashchenko, et al.; Ed. by Sychev DA, Ostroumova OD, Pereverzev AP. Moscow: Prometej, 2022. (In Russ).